Chenguang Tianrun Pharmaceutical was established on May 24, 2019. It is an enterprise focusing on the research and development, production and sales of raw materials and pharmaceutical intermediates. On July 11, 2024 and September 23, 2024, sodium valproate and valproic acid raw materials were successfully accepted by the